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A B S T R A C T
Peptidoglycan (PG) is an essential component of the bacterial cell wall that maintains the shape and integrity of
the cell. The PG precursor lipid II is assembled at the inner leaflet of the cytoplasmic membrane, translocated to
the periplasmic side, and polymerized to glycan chains by membrane anchored PG synthases, such as the class A
Penicillin-binding proteins (PBPs). Polymerization of PG releases the diphosphate form of the carrier lipid,
undecaprenyl pyrophosphate (C55-PP), which is converted to the monophosphate form by membrane-embedded
pyrophosphatases, generating C55-P for a new round of PG precursor synthesis. Here we report that deletion of
the C55-PP pyrophosphatase gene pgpB in E. coli increases the susceptibility to cefsulodin, a β-lactam specific for
PBP1A, indicating that the cellular function of PBP1B is impaired in the absence of PgpB. Purified PBP1B in-
teracted with PgpB and another C55-PP pyrophosphatase, BacA and both, PgpB and BacA stimulated the gly-
cosyltransferase activity of PBP1B. C55-PP was found to be a potent inhibitor of PBP1B. Our data suggest that the
stimulation of PBP1B by PgpB is due to the faster removal and processing of C55-PP, and that PBP1B interacts
with C55-PP phosphatases during PG synthesis to couple PG polymerization with the recycling of the carrier
lipid and prevent product inhibition by C55-PP.
Introduction
Peptidoglycan (PG) is an essential component of the bacterial cell
envelope protecting the cells from bursting due to its turgor and
maintaining the shape of the cell. PG forms a continuous structure,
called sacculus, consisting of glycan chains of alternating N-acet-
ylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) residues
connected by short peptides (Vollmer et al., 2008). Growing and di-
viding cells enlarge their sacculus by incorporation of nascent PG that is
synthesized from the precursor lipid II (Fig. 1). The two final PG pre-
cursors contain a carrier lipid, undecaprenyl phosphate (C55-P) and are
assembled at the inner leaflet of the cytoplasmic membrane. First, the
transferase MraY produces lipid I from the soluble nucleoside-pre-
cursors UDP-MurNAc-pentapeptide and the carrier lipid, C55-P
(Barreteau et al., 2008). Second, MurG catalyses the transfer of a
GlcNAc moiety from UDP-GlcNAc to lipid I, forming lipid II (Liu &
Breukink, 2016). Lipid II is then translocated across the cytoplasmic
membrane by proteins belonging to the SEDS (shape, elongation, di-
vision and sporulation) family, MurJ or both, and polymerized by PG
glycosyltransferases (GTases) (Ruiz, 2015, Leclercq et al., 2017,
Mohammadi et al., 2011).
Escherichia coli has six PG synthases of which two semi-redundant
bifunctional GTase-TPases, the Penicillin-binding proteins (PBPs)
PBP1A and PBP1B (Yousif et al., 1985), play major roles in PG synthesis
during cell elongation and division. These enzymes are anchored to the
cytoplasmic membrane by a single N-terminal transmembrane helix
and are engaged in a number of protein-protein interactions within
dynamic multi-protein complexes presumably to regulate their activ-
ities (Typas et al., 2012). PBP1A and PBP1B are both regulated by a
cognate outer membrane-anchored lipoprotein – LpoA and LpoB, re-
spectively (Typas et al., 2010, Paradis-Bleau et al., 2010) – which is
needed to activate the PBP through the PG layer presumably in re-
sponse to the properties of the pores in the PG layer (Typas et al., 2012).
The stimulation of PBP1B by LpoB is modulated by CpoB and TolA to
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coordinate outer membrane constriction with the synthesis of septal PG
(Gray et al., 2015).
The polymerization of new glycan strands occurs at the outer leaflet
of the cytoplasmic membrane and releases the carrier lipid in the di-
phosphate form, undecaprenyl pyrophosphate (C55-PP). C55-PP is also
synthesised de novo at the inner leaflet of the cytoplasmic membrane by
UppS (Teng & Liang, 2012), and needs to be dephosphorylated to C55-P
which is the universal carrier lipid not only for PG precursors, but also
for precursors for the O-antigen moiety of lipopolysaccharide (LPS), the
enterobacterial common antigen and colanic acid (Manat et al., 2014).
In E. coli, C55-PP molecules can be dephosphorylated on the peri-
plasmic side of the membrane by four undecaprenyl pyrophosphate
phosphatases (UPPs), BacA (UppP) and three members of the type 2
phosphatidic acid phosphatase family (PAP2), PgpB, YbjG and LpxT
(Fig. 1). Their collective activity is essential. However, only PgpB, YbjG
and BacA can sustain growth in the absence of all other phosphatases
(El Ghachi et al., 2005). LpxT has also phosphotransferase activity,
transferring a phosphate from C55-PP to the LPS precursor lipid A
(Touzé et al., 2008b). BacA is widely conserved in bacteria (Bickford &
Nick, 2013) and contributes to ∼75% of the UPP activity in E. coli (El
Ghachi et al., 2005). Whilst BacA is specific for C55-PP, PgpB has a
more relaxed substrate specificity, also participating in the phosphati-
dylglycerol metabolism (Touzé et al., 2008a, Fan et al., 2014).
Here we show that the deletion of pgpB increases the susceptibility
of E. coli cells to cefsulodin, indicating an impaired function of PBP1B.
PgpB and PBP1B formed a complex in vitro as demonstrated by pull
down and surface plasmon resonance experiments. C55-PP inhibited
the GTase activity of PBP1B and both, BacA and PgpB stimulated PBP1B
in detergents and when reconstituted in membranes. Hence, our data
suggest that the GTase and C55-PP dephosphorylation reactions are
coupled and that this coupling prevents the product inhibition of the
GTase active site.
Materials and methods
Chemicals
[14C]GlcNAc-labelled lipid II and dansylated lipid II were prepared
as published (Breukink et al., 2003, Bertsche et al., 2005). Unlabelled
lipid II was purchased from the BACWAN facility (Warwick, UK). Polar
lipid extract from E. coli, 1,2-dipalmitoleoyl-sn-glycero-3-phosphocho-
line (DOPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-gly-
cerol) (POPG) and tetraoleoyl cardiolipin (TOCL) were obtained from
Avanti Polar Lipids (Alabaster, USA). Lipids were resuspended in
chloroform:methanol (2:1) at a concentration of 20 g/L, aliquoted and
stored at −20 °C. Farnesyl pyrophosphate (C15-PP), isopentenyl pyr-
ophosphate (C5-PP), Triton X-100, phenylmethylsulfonyl fluoride
(PMSF), protease inhibitor cocktail (PIC) and β-mercaptoethanol were
from Millipore Sigma. Undecaprenyl monophosphate diammonium salt
(C55-P) was obtained from Larodan (Solna, Sweden). Upon arrival,
C55-P was dried and resuspended in chloroform:methanol (2:1) at a
final concentration of 1mM. n-dodecyl-beta-D-maltopyranoside (DDM)
was purchased from Anatrace (Maumee, USA). All other chemicals were
from Millipore Sigma (Gillingham, UK).
Bacterial strains and plasmids
Bacterial strains and plasmids used in this work are listed in
Supplementary Table 1.
Cloning of overexpression plasmids
DNA encoding for BacA, PgpB and UppS was amplified by PCR from
genomic DNA of E. coli BW25113 using the appropriate oligonucleo-
tides (Supplementary Table 2) and cloned into pET28a(+) with the
appropriate restriction enzymes (Supplementary Table 2) generating
the overexpression plasmids pET28a-bacA, pET28a-pgpB and pET28a-
ispU, respectively. pET28a-pgpB-mut was generated from pET28a-pgpB
by introducing a point mutation using the QuikChange Lightning Kit
(Agilent) and the oligonucleotides listed in Supplementary Table 2 and
used for the overproduction of the inactive version PgpB(D211E).
Purification of proteins
Purification of PgpB and PgpB(D211E)
PgpB and the inactive PgpB(D211E) version were purified according
Fig. 1. Membrane-associated steps in PG synthesis in
Escherichia coli. The precursor lipid II is synthesized
at the inner leaflet of the cytoplasmic membrane in
two steps. MraY transfers MurNAc(pentapeptide)-
phosphate from UDP-MurNAc-pentapeptide to the
carrier lipid undecaprenyl phosphate (C55-P) to
form lipid I. MurG transfers GlcNAc from UDP-
GlcNAc to lipid I producing lipid II. Lipid II is then
flipped to the outer leaflet of the cytoplasmic mem-
brane and polymerized by glycosyltransferase activ-
ities of PBPs, releasing undecaprenyl pyrophosphate
(C55-PP). C55-PP is dephosphorylated by the peri-
plasmic phosphatases BacA, PgpB and YbjG, and
transported back to the inner leaflet to start a new
cycle.
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to (Touzé et al., 2008a) with modifications. PgpB was overproduced in
E. coli C43(DE3) cells grown in 2YT medium at 37 °C to an OD600 of 0.8.
Overproduction was induced by addition of 1mM IPTG (final con-
centration). After 3.5 h of incubation at 37 °C cells were harvested by
centrifugation for 15min at 7,000g and 14 °C. The cell pellet was re-
suspended in 40mL of buffer P1 (20mM Tris/HCl pH 7.5, 500mM
NaCl, 1 mM MgCl2, 20mM β-mercaptoethanol, 10% glycerol) supple-
mented with 1mM PMSF, 1× protease inhibitor cocktail (PIC) and
deoxyribonuclease I (Sigma Aldrich). Cells were broken by sonication
and centrifuged for 1 h at 130,000× g and 4 °C. The membrane fraction
containing pellet was resuspended in 40mL buffer P2 (20mM Tris/HCl
pH 7.5, 500mM NaCl, 1 mM MgCl2, 10mM β-mercaptoethanol, 10%
glycerol, 1% DDM) supplemented with 1mM PMSF and 1× PIC and
stirred overnight at 4 °C. Insoluble material was removed by cen-
trifugation for 1 h at 130,000g at 4 °C. The supernatant was recovered,
mixed with 2mL Ni-NTA Superflow (Qiagen) preequilibrated in buffer
P3 (20mM Tris/HCl pH 7.5, 500mM NaCl, 1 mM MgCl2, 10mM β-
mercaptoethanol, 10% glycerol, 0.05% DDM) supplemented with
10mM imidazole and gently stirred overnight at 4 °C. Ni-NTA agarose
was poured in a gravity flow column and washed 10 times with 8mL of
buffer P3 supplemented with imidazole (5 times with 10mM and
5 times with 30mM). PgpB was eluted with buffer C supplemented with
400mM imidazole. Eluted protein was dialysed against 2 L dialysis
buffer (20mM Tris/HCl pH 7.4, 150mM NaCl, 10mM β-mercap-
toethanol, 10% glycerol). The combined fractions were concentrated
using a Vivaspin Turbo 15 ultrafiltration unit (Sartorius, Göttingen,
Germany) and stored in aliquots at −80 °C.
Purification of BacA
BacA was purified according to (Manat et al., 2015) with mod-
ifications. BacA was overproduced in E. coli C43(DE3) cells grown in
2YT medium at 37 °C to an OD600 0.7. Overproduction was induced by
addition of IPTG to a final concentration of 1mM and incubation
continued overnight at 22 °C. Cells were harvested by centrifugation for
15min at 7,000× g and 14 °C. The resulting cell pellet was re-
suspended in 40mL buffer B1 (25mM Tris/HCl pH 7.2, 150mM NaCl,
5 mM β-mercaptoethanol, 10% glycerol) supplemented with 1mM
PMSF, 1× PIC and deoxyribonuclease I (Sigma Aldrich). Cells were
broken by sonication and centrifuged for 1 h at 130,000g and 4 °C. The
pellet was resuspended in 60mL buffer B2 (25mM Tris/HCl pH 7.2,
300mM NaCl, 5 mM β-mercaptoethanol, 20% glycerol, 2% DDM)
supplemented with 1mM PMSF and 1× PIC (as before) and stirred
overnight at 4 °C. Insoluble material was removed by centrifugation for
1 h at 130,000g at 4 °C. The supernatant was recovered and further
purified using immobilized metal affinity chromatography (IMAC) in a
5mL HisTrap column (GE Lifesciences) equilibrated in buffer B3
(25mM Tris/HCl pH 7.2, 300mM NaCl, 5 mM β-mercaptoethanol, 20%
glycerol, 0.1% DDM) supplemented with 10mM imidazole. The column
was washed with 5 column volumes (CV) of buffer B3 supplemented
with 10mM imidazole and with 5 CV of buffer B3 supplemented with
50mM imidazole. BacA was eluted using buffer B3 supplemented with
300mM imidazole. Fractions containing BacA were combined and
dialysed against buffer B4 (25mM Tris/HCl pH 7.2, 300mM NaCl,
5 mM β-mercaptoethanol, 10% glycerol). Optionally, the oligohistidine
tag was removed by addition of 2.5 units/mL of thrombin (Novagen)
while dialysing in buffer B4 for 20 h. The protein was further purified
using gel filtration chromatography on a Superdex 200 HiLoad 16/60
column (GE Healthcare) equilibrated in buffer B3 at 1mL/min. Frac-
tions were analysed using SDS-PAGE and fractions containing BacA
were combined, concentrated using a Vivaspin Turbo 15 ultrafiltration
unit (Sartorius, Göttingen, Germany) and stored in aliquots at −80 °C.
Purification of UppS
UppS was purified according to (Pan et al., 2000) with modifica-
tions. UppS was overproduced in E. coli BL21(DE3) (Novagen) cells
grown in LB medium at 37 °C to an OD600 of 0.6. Overproduction was
induced by addition of IPTG to a final concentration of 1mM. After
3.5 h of incubation at 37 °C cells were harvested by centrifugation for
15min at 7,000g and 14 °C. The resulting cell pellet was resuspended in
80mL buffer (25mM Tris/HCl pH 7.8, 150mM NaCl) supplemented
with 1mM PMSF, 1× PIC and deoxyribonuclease I. Cells were broken
by sonication and centrifuged for 1 h at 130,000g and 4 °C. The su-
pernatant was mixed with 2mL Ni-NTA Superflow preequilibrated in
buffer (supplemented with 5mM imidazole) and gently stirred at 4 °C
for 2–3 h. Ni-NTA agarose was poured in a gravity flow column, washed
5 times with 10 column volumes of buffer supplemented with 30mM
imidazole. UppS was eluted with buffer supplemented with 300mM
imidazole. Eluted protein was dialysed against 2 L buffer and further
purified by size exclusion chromatography on a Superdex 200 HiLoad
16/60 column (GE Healthcare) using the same buffer and a flowrate of
1mL/min. Fractions containing UppS were combined, concentrated
using a Vivaspin Turbo 15 ultrafiltration unit (Sartorius, Göttingen,
Germany) and stored in aliquots at −80 °C.
Other proteins
PBP1B (Bertsche et al., 2006, Typas et al., 2010), PBP1A (Born
et al., 2006) and LpoB (Egan et al., 2014) were purified as described.
Cefsulodin susceptibility assays
Disc diffusion assays were carried out as described by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST) with
modifications (EUCAST, 2017). Briefly, 10mL fresh Mueller-Hinton
broth was inoculated with material from one bacterial colony and
grown until the OD600 reached 0.5. The cell suspension was diluted to
an OD600 of 0.125, 1mL was centrifuged for 1min at 3500g and re-
suspended in 1mL of 0.9% NaCl. Bacteria were evenly distributed onto
a fresh Mueller-Hinton II agar plate with 4mm agar thickness using a
cotton swab soaked with the cell suspension. The plate was allowed to
dry for 5 min and a paper disc containing 30 µg cefsulodin was placed
in the centre. Plates were incubated for 18 h at 37 °C. A high resolution
picture was taken for each plate and the diameter of the growth in-
hibition zone was determined using the program ImageJ.
Cell viability assay (spot-plate-assay)
Overnight cultures of the test strains grown in Mueller-Hinton broth
were diluted to an OD600 of 2. A serial dilution series (100 to 10−7) was
prepared in Mueller-Hinton broth using a 96-well plate. Cells from each
dilution step were applied on Mueller-Hinton II agar plates containing
32 µg/mL cefsulodin using a replica plater (Sigma Aldrich), dried and
incubated for 18 h at 37 °C. For growth control Mueller-Hinton II agar
plates without antibiotic were used.
In vitro pull down assay with or without cross-linking
Proteins were mixed in 200 μL of binding buffer (10mM HEPES/
NaOH, 10mM MgCl2, 300mM NaCl, 0.1% Triton X-100, pH 7.5). The
protein concentrations were 1.5 or 2.0 μM for PBP1A or PBP1B, 3 μM
for PgpB-ht and 5 μM for ht-BacA. Samples were incubated at ambient
temperature for 10min to allow possible complexes to form. If cross-
linking was required, 0.2% (w/v) formaldehyde (Millipore Sigma) was
added followed by incubation at 37 °C for 10min. Excess cross-linking
was blocked by addition of 100mM Tris/HCl, pH 7.5. Complexes were
pulled down by O/N incubation at 4 °C with 100 µL of washed and
equilibrated Ni-NTA superflow beads (QIAGEN, Hilden, Germany).
Beads were washed 5–8 times with 1.5 mL of wash buffer (10mM
HEPES/NaOH, 10mM MgCl2, 500mM NaCl, 50mM imidazole, 0.05%
Triton X-100, pH 7.5). For samples without cross-linker a lower imi-
dazole concentration of 20mM was used in the wash buffer. Retained
proteins were eluted by boiling the beads in SDS-PAGE loading buffer;
beads were then removed, and samples resolved by SDS-PAGE. Gels
V.M. Hernández-Rocamora et al. The Cell Surface 2 (2018) 1–13
3
were stained with Coomassie brilliant blue (Carl Roth, Germany).
Reconstitution of PBP1B, PgpB and BacA in liposomes
Proteoliposomes containing PBP1B in the presence or absence of
BacA or PgpB were prepared as described previously with some mod-
ifications (Egan et al., 2015, Rigaud & Lévy, 2003). The appropriate
lipid or mixture of lipids were dried in a glass test tube under stream of
N2 to form a lipid film followed by desiccation under vacuum from 2 h.
Resuspension into multilamellar vesicles (MLVs) was achieved by ad-
dition of the indicated buffer (see below) and several cycles of vigorous
mixing and short incubations in hot tap water. E. coli polar lipids were
resuspended in 20mM Tris/HCl pH 7.5 while 20mM Tris/HCl pH 7.5,
150mM NaCl was used for artificial lipids. The final lipid concentration
was 5 g/L. To form large unilamellar vesicles (LUVs), MLVs were sub-
jected to 10 freeze-thaw cycles and then extruded 10 times through a
0.2 µm filter. LUVs were destabilised by the addition of Triton X-100 to
an effective detergent:lipid ratio of 1.40 and mixed with proteins in a
1:3000 lipid:PBP1B molar ratio and 1:1 PBP1B:phosphatase molar
ratio. After incubation at 4 °C for 1 h, prewashed Biobeads SM2
(BioRad, USA; 100mg per 3 µmol of Triton X-100) were added to the
sample to remove detergents. Biobeads were exchanged after 2 and
16 h, followed by incubation with fresh Biobeads for a further 2 h. After
removal of Biobeads by short centrifugation at 4,000g, liposomes were
pelleted at 250,000g for 30min at 4 °C. The pellet containing proteo-
liposomes was resuspended in the appropriate buffer and analysed by
SDS-PAGE and a bicinchoninic acid assay (Pierce BCA Assay Kit, The-
moFisher Scientific, USA) to determine protein concentration. The size
of LUVs and proteoliposomes was confirmed using dynamic light scat-
tering (DLS) using a Zetasizer instrument (Malvern Technologies, UK).
Phosphatase assay for PgpB and BacA
Phosphatase assays were carried out as previously described (Touzé
et al., 2008a). Assays were performed with a total volume of 50 µl in
buffer containing 20mM Tris/HCl pH 7.5, 150mM NaCl, 10 mM β-
mercaptoethanol, 0.02% DDM, and 10mM MgCl2. The substrate far-
nesyl pyrophosphate (Millipore Sigma) was added at a range of con-
centrations from 5 to 80 µM. The enzyme concentrations were 42 nM
PgpB, 42 nM BacA, and 66 nM PBP1B. After incubation for 15min at
ambient temperature 140 µL Biomol Green reagent (Enzo Life Sciences,
BML-AK111-0250) was added and samples were incubated for 30min
at ambient temperature to allow for colour development. Absorbance at
620 nm was measured in a SpectraMax M2 spectrophotometer. In-
organic phosphate standard provided with the Biomol Green reagent
was used to obtain a standard curve that was used to convert enzyme
assay absorbance into phosphate concentration. The enzyme kinetics
curves were analysed using classical Michaelis–Menten equation using
the Excel add-on, Solver.
C55-PP synthesis by UppS
C55-PP synthesis reaction was carried out as described in (Pan et al.,
2000) with minor modifications. The reaction contained 50mM
HEPES/KOH pH 7.5, 50mM KCl, 0.5mM MgCl2, 0.1% Triton X-100,
2 nmol C15-PP, 22 nmol C5-PP and 10 µM UppS. Each reaction was
incubated for 4 h at 25 °C under continuous shaking (600 rpm).
Continuous glycosyltransferase (GTase) assay
Continuous fluorescence GTase assays using dansylated lipid II were
performed as published (Banzhaf et al., 2012, Egan & Vollmer, 2016).
Samples contained 50mM HEPES/NaOH pH 7.5, 150mM NaCl, 10mM
MgCl2 0.04% Triton X-100 and 0.01% DDM (reactions with BacA) or
0.006% DDM (reactions with PgpB) in a final volume of 60 µL. PBP1B
and phosphatases were added at a concentration of 0.5 µM and 1 µM,
respectively. When indicated, LpoB(sol) was added at a concentration
of 2 µM. Reactions were started by the addition of dansylated lipid II to
a final concentration of 10 µM and monitored by following the decrease
in fluorescence over 30min at 37 °C using a FLUOstar OPTIMA plate
reader (BMG Labtech, Germany) with excitation at 330 nm and emis-
sion at 520 nm. The fold-increase in GTase rate was calculated against
the mean rate obtained with PBP1B alone at the same reaction condi-
tions, at the fastest rate.
The assay was modified to test the effects of C55-P or C55-PP on
GTase activity. First, reactions to synthesise C55-PP with UppS and the
substrates C5-PP and C15-PP were carried out as described above. Then
these samples were mixed with PBP1B, LpoB in the presence or absence
of PgpB or PgpB(D211E). Control reactions were performed in which
either only the substrates, only UppS or the UppS buffer were added.
Samples had a final volume of 60 µL and contained 50mM HEPES/KOH
pH 7.5, 115mM KCl, 35 mM NaCl, 0.5mM MgCl2, 1.2 mM β-mercap-
toethanol, 1.3% glycerol, 0.035% Triton X-100, 0.006% DDM, 50 µM
moenomycin (only for negative controls), 3.09 µM UppS, 0.14mg/mL
cellosyl, 1 µM PgpB or PgpB(D211E), 0.5 µM PBP1B and 1 µM LpoB.
Sample further contained either 33.3 µM C55-PP (from reactions with
UppS and substrates), 33.3 µM C15-PP and 333.3 µM C5-PP (mock re-
actions with substrates) or 33.3 µM C55-P. Reactions were started by
adding dansylated lipid II to a final concentration of 10 µM and mon-
itored by following the decrease in fluorescence over 60min at 25 °C
using a FLUOstar OPTIMA plate reader as described above.
In vitro peptidoglycan synthesis assay using radiolabelled lipid II
To assay the in vitro PG synthesis activity of PBP1B with radi-
olabelled lipid II substrate in the presence of detergent we used a pre-
viously published assay (Banzhaf et al., 2012, Biboy et al., 2013). Final
reactions included 10mM HEPES/NaOH pH 7.5, 150mM NaCl, 10mM
MgCl2 0.05% Triton X-100 and 0.027% DDM. The concentration of
PBP1B was 0.5 or 0.05 µM, and BacA and PgpB were added at a con-
centration of 2 µM. Reactions were carried out for 1 h at 37 °C. The
same methodology with minor modifications was used to assay the in
vitro PG synthesis activity of PBP1B in liposomes. To start reactions,
1.5 nmol [14C]-labelled lipid II were dried in a 0.5mL glass tube using a
vacuum concentrator, resuspended in 5 µL of the appropriate liposome
buffer, and mixed with liposomes, buffer and MgCl2 to a total volume of
50 µL. Final reactions contained 0.5 µM PBP1B, 30 µM lipid II and 1mM
MgCl2 in 20mM Tris/HCl pH 7.5. Samples were incubated for 90min at
37 °C with shaking at 800 rpm. Reactions were stopped by boiling for
5min. Digestion with cellosyl, reduction with sodium borohydride and
analysis by HPLC were performed as described (Biboy et al., 2013).
Coupled PG synthesis/C55-PP phosphatase assay in liposomes
Phosphatase assays were carried out in a final volume of 50 µl
containing 10mM Tris/HCl pH 7.5, 150mM NaCl, 1 mM MgCl2,
0.5 mM CaCl2, 40 µM lipid II, 0.95 µM protein (protein content in li-
posomes), 1 µM LpoB(sol) and 2 nmol lipid II. The mixture was in-
cubated for 4 h at 37 °C. Reactions were terminated by adding 50 µl n-
butanol/pyridine acetate pH 4.2 (2:1). Samples were vortexed for 1min
and centrifuged for 3min at 17,000g on a bench top centrifuge. The
reaction products present in the organic phase were analysed by TLC on
HPTLC alumina silica gel 60 plates (Merck KgaA) using chloroform-
methanol-water-ammonia (88:48:10:1) as the mobile phase (Rick et al.,
1998). TLC bands were stained with iodine and quantified using ImageJ
software, the data were analysed using Excel.
Surface plasmon resonance (SPR) experiments
PBP1A and PBP1B were immobilised covalently on an SPR sen-
sorchips as previously described (Egan et al., 2014). PgpB was injected
in 10mM Tris/maleate pH 7.5, 150mM NaCl, 5 mM imidazole, 5 mM β-
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mercaptoethanol, 0.05% DDM; BacA was injected in 10mM Tris/mal-
eate at pH 7.5, 300mM NaCl, 0.1% Triton X-100. The concentration of
PgpB injected ranged from 0.125–2 μM. BacA was injected at a con-
centration range of 0.163–3 μM. Assays were performed in triplicate at
25 °C and a flow rate of 75 μL/min, and with an injection time of 5min.
Binding curves were obtained by plotting the equilibrated response
signal at the end of the injection minus the signal from the channel
without immobilized protein, against ligand concentration. The re-
sulting binding curves were fitted using the non-linear least squares
method to a model for 1:1 binding described by Eq. (1) in which R is the
SPR signal at the equilibrium, Rmax the maximum response, KD the
dissociation constant and C the analyte concentration.
=
+
R
K
R ·C
CD
max
(1)
The non-linear regression was performed using SigmaPlot 13 soft-
ware (Systat Software Inc.).
Structural model for the PgpB-PBP1B complex
The docking models of PgpB-PBP1B complex were built using
HADDOCK2.2 data-driven docking protocols (Dominguez et al., 2003)
and CNS1.2 (Brünger et al., 1998) for the structure calculations. The
initial coordinates of E. coli PgpB (PDB code 5JWY (Tong et al., 2016))
and E. coli PBP1B (PDB code 5HLD (King et al., 2017)) were used and
the docking energy minimization occurred with a minimal conforma-
tional rearrangement of the partners. The multi domain docking was
driven with ambiguous interaction restraints between the transmem-
brane helix of PBP1B (active residues 74–96) and PgpB (passive re-
sidues 1–235). The HADDOCK score was used to rank the generated
models (Lutje Hulsik et al., 2013).
Results
PgpB deletion affects the function of PBP1B in the cell
The β-lactam cefsulodin targets PBP1A from E. coli with high affi-
nity and an IC50 of 0.47 μg/mL. It also inhibits the homologous PBP1B
with an IC50 of 3.7 μg/mL but does not target any other PBP in E. coli at
a workable concentration (Curtis et al., 1979). Because the cell needs
either PBP1A or PBP1B for growth, any condition or mutation that af-
fects PBP1B function causes a higher susceptibility for cefsulodin. When
testing the cefsulodin susceptibility of different E. coli mutants either by
measuring the inhibition zone in a disc diffusion assay (Fig. 2A) or by a
spot plate based cell viability assay (Fig. 2B) we first confirmed that a
ΔmrcB mutant (lacking PBP1B), but not a ΔmrcA mutant (lacking
PBP1A) showed a higher susceptibility compared to E. coli wild-type,
indicating that indeed PBP1B becomes more important in cells growing
in the presence of cefsulodin (Sarkar et al., 2012). Moreover, we no-
ticed that a mutant lacking the C55-PP pyrophosphatase PgpB displayed
increased sensitivity to cefsulodin (Fig. 2). Mutants lacking BacA or
YbjG had similar sensitivities to cefsulodin as the wild-type (Fig. 2).
These data suggest that the functionality of PBP1B might be reduced in
the cell when PgpB is absent.
PgpB interacts with PBP1B
The phenotypic analysis of the ΔpgpB mutant and the proximate
position of PgpB and PBP1B in the PG synthesis pathway - the product
of PBP1B is the substrate of PgpB - pointed to a possible interaction
between both proteins. To test this possibility we purified both proteins,
the second major bi-functional PG synthase, PBP1A and the major C55-
PP phosphatase BacA, for protein-protein interaction studies. A C-
terminal His6-tagged version of PgpB (Touzé et al., 2008a), PgpB-ht,
was used in pull-down assays with non-tagged PBP1A or PBP1B initially
in the presence of the chemical cross-linker formaldehyde, followed by
incubation with Ni-NTA beads to capture PgpB-ht along with any pro-
teins associated with it. PgpB-ht was able to pull down untagged PBP1B
but not untagged PBP1A (Fig. 3A and B). Both PBPs were not pulled
down by the beads in the absence of PgpB-ht. PgpB-ht also pulled down
untagged PBP1B in the absence of the cross-linker (Fig. 3C), suggesting
that both proteins interact directly.
To verify the specific interaction between PgpB and PBP1B, we used
surface plasmon resonance (SPR) experiments in which PBP1A or
PBP1B were covalently immobilized via their TPase active site to sur-
faces with bound ampicillin (Fig. 3D). PgpB bound strongly to a surface
containing PBP1B, while the binding of PgpB to a control surface
without protein or a surface with immobilized PBP1A was significantly
weaker. This indicated a specific interaction between PgpB and PBP1B
but not with PBP1A, in agreement with our pull down assays. The
binding of PgpB to surfaces with immobilized PBP1B increased in a
concentration-dependent manner. These binding responses could be fit
to a 1:1 binding model yielding an apparent dissociation constant of
1.05 ± 0.06 µM (Fig. 3E).
In addition to PgpB, we also tested BacA for possible interactions
with PBP1A or PBP1B (Fig. S1). An N-terminal His6-tagged version, ht-
Fig. 2. A ΔpgpB mutant shows increased susceptibility to cefsulodin. (A) The growth inhibition zone around discs loaded with 30 µg of cefsulodin was significantly
increased in the mutant strain lacking PgpB compared to wt strain (BW25113) or strains lacking BacA, YbgG or PBP1A (ΔmrcA). As expected, the mutant lacking
PBP1B (ΔmrcB) was hyper-susceptible to cefsulodin. The data are mean ± SD of three independent experiments. (B) Spot plate assay showing the increased
susceptibility of the ΔpgpB mutant on plates containing 32 µg/mL cefsulodin.
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BacA, was purified according to published protocols (Manat et al.,
2015) and used in pull down assays with non-tagged PBP1B in the
presence or absence of the cross-linker formaldehyde (Fig. S1A and B).
ht-BacA was able to pull down PBP1B independently of the addition of
cross-linker, indicating an interaction between both proteins. In order
to further characterize this interaction, we performed SPR experiments,
injecting BacA onto surfaces containing covalently immobilised PBP1A
or PBP1B, as done before for PgpB (Fig. S1C). We detected a slightly
higher binding signal when BacA was injected onto the PBP1B surface
compared to the signal obtained for the PBP1A-containing surface or
the control surface without protein (Fig. S1D and E). However, BacA
bound significantly to the control surface (dextran with immobilized
and hydrolysed ampicillin) and we could not reach a sufficiently high
concentration of BacA to saturate the binding to the PBP1B surface,
preventing calculation of a binding constant (Fig. S1E).
PgpB and BacA stimulate PBP1B activity in detergents
The physical interactions between C55-PP phosphatases and PBP1B
could allow the successive reactions of both enzymes to be coupled,
affecting the reaction rates. Therefore we tested first whether the pre-
sence of PBP1B affects the phosphatase activity of PgpB or BacA, and
second whether the presence of BacA or PgpB affected PG synthesis by
PBP1B.
We measured the activities of PgpB or BacA in the presence or ab-
sence of PBP1B, using farnesyl pyrophosphate (C15-PP) as substrate
(Fig. 4A and B). The presence of PBP1B had only small effects, slightly
increasing the Km and kcat values. The strongest effect was on BacA
activity, which had a Km of 20 ± 4 µM without PBP1B and 46 ± 3 µM
with PBP1B. The increase in kcat in the presence of PBP1B was ∼1.3-
fold for both phosphatases (Fig. 4C). PBP1B did not have phosphatase
activity on its own (data not shown).
We next performed in vitro PG synthesis assays to assess the effect of
phosphatases on the GTase and TPase activities of PBP1B (Figs. 5 and
S2). The continuous GTase assay uses fluorescently labelled lipid II
(dansyl-lipid II) and the PG polymers produced are digested to mur-
opeptides with reduced fluorescence. We assayed PBP1B at two con-
centrations (0.5 and 0.05 µM, respectively) with or without its activator
LpoB and in the presence or absence of PgpB and BacA (Fig. S2). PBP1B
has poor activity at the lower concentration (Müller et al., 2007) and by
Fig. 3. PgpB interacts with PBP1B but not with PBP1A. (A) Oligohistidine tagged PgpB (PgpB-ht) and PBP1A alone, or both proteins together were incubated with
chemical cross-linker and followed by pull-down to Ni-NTA beads. PgpB-ht did not interact with PBP1A. PgpB-ht did pull down PBP1B to Ni-NTA beads in the
presence (B) or absence (C) of chemical cross-linker. Lanes labelled with A correspond to samples applied to the Ni-NTA beads and E to the elution. (D) PBP1A, PBP1B
or no protein were immobilized on a sensor chip with bound ampicillin. PgpB-ht was applied at concentrations of 2, 1, 0.5, 0.25 or 0.125 µM. PgpB-ht bound to
immobilised PBP1B but not to PBP1A or the control surface. (E) Analysis of the titration data in panel D using a 1:1 binding model yields an apparent KD of
1.05 ± 0.06 µM (three independent experiments).
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testing this condition we would detect a potentially stimulatory effect.
As shown before (Egan et al., 2014), PBP1B had a significant higher
relative GTase rate in the presence of LpoB. However, neither BacA nor
PgpB affected the GTase rate of PBP1B at any of the conditions tested
(Fig. S2C and F).
We then used an end point assay with radiolabelled lipid II to test
the coupled GTase and TPase activities of PBP1B. The PG produced was
digested with the muramidase cellosyl and the resulting muropeptides
we separated by high-pressure liquid chromatography (HPLC) (Fig. 5).
This assay does not measure enzyme kinetics but has the advantage that
both activities of PBP1B can be monitored in the same sample with the
chemically unaltered substrate. As before, we assayed PBP1B at con-
centrations of 0.5 and 0.05 µM, respectively, and in the presence or
absence of each phosphatase (Fig. 5A). At the high concentration of
PBP1B, PgpB and BacA did not affect the amount of PG produced
(Fig. 5B) and did not significantly affect the amount of TPase products,
the cross-linked muropeptides (Fig. 5C). At the low concentration of
PBP1B, PgpB and BacA stimulated the consumption of lipid II and the
amount of cross-linked muropeptides (Fig. 5B and C). Moreover, the
stimulatory effect of PgpB was higher than that of BacA (Fig. 5B and C).
In summary, we detected a small but significant stimulatory effect of
PBP1B on BacA and PgpB, and an activation of PBP1B at low con-
centration by both phosphatases.
PgpB and BacA stimulate PBP1B in liposomes
The enzymatic assays described above were carried out in the pre-
sence of detergents with the solubilized membrane enzymes. However,
detergents may affect the activity of membrane proteins and the dif-
fusion of substrates and proteins in a membrane system is different from
the three-dimensional diffusion occurring in detergents, which could
hide or distort the effects of the coupling of the two reactions. To
measure the activities of PBP1B in a more physiological environment
we reconstituted it in liposomes in the presence or absence of BacA or
PgpB. We prepared these liposomes with either E. coli polar lipids
(EcPL), an extract of natural lipids from E. coli, or DOPC:POPG:TOCL
70:20:10 (molar ratio), a mixture of artificial lipids matching the con-
tents of lipids in EcPL except for the substitution of phophatidyletha-
nolamine with phosphatidylcholine to improve liposome stability. We
found that the activity of PBP1B was higher in liposomes prepared from
the natural lipid extract than the artificial lipids (Fig. S3) and used these
in most activity assays. Liposomes made of artificial lipids were only
used when assaying phosphatase activity because we realized that EcPL
contains a significant amount of C55-P that can be detected in the thin
layer chromatography (TLC) assays (data not shown).
We reconstituted PBP1B in EcPL liposomes either alone or in com-
bination with BacA or PgpB at a molar ratio of 1:1. After reconstitution,
we assayed PBP1B activity by the addition of radioactively-labelled
lipid II, which is incorporated into the bilayer and consumed by PBP1B.
The products of the reaction were digested with cellosyl and analysed
by HPLC (Fig. 6A). The chromatograms revealed an increase in the
amount of PG produced by PBP1B when phosphatases were present
(Fig. 6B). Remarkably, this stimulatory effect was also seen in the
presence of the inactive PgpB(D211E) mutant in the liposomes
(Fig. 6B). Finally, there was no significant effect on the cross-linkage of
the PG product due to the presence of phosphatases (Fig. 6C).
Next, we assayed coupled PG synthesis and phosphatase activities
on liposomes. PBP1B was reconstituted into liposomes made of artificial
lipids as described above, in the presence or absence of BacA or PgpB at
a molar ratio of 1:1. Due to the low activity of PBP1B in the presence of
artificial lipids we added a soluble version of its cognate activator, LpoB
(sol). The PG synthesis reaction was started by adding lipid II. After the
reaction all lipids were extracted with n-butanol/pyridine acetate and
analysed by TLC, which also contained lanes with C55-P and lipid II
standards, and lipid extract from protein-free liposomes (Fig. 6D). Lipid
II consumption was observed as the disappearance of the lipid II band in
comparison to the standard. We also quantified the band corresponding
to C55-P produced by the phosphatases but were unable to precisely
quantify C55-PP due to a buffer component migrating to a similar po-
sition on the TLC plate. Liposomes carrying only PBP1B consumed less
than 20% of the total lipid II, and the band corresponding to the C55-PP
was also visible (Fig. 6D and E). When liposomes contained both,
Fig. 4. PBP1B has a mild effect on the phosphatase activities of PgpB and BacA. (A) Activity of PgpB against in farnesyl pyrophosphate the presence or absence of
PBP1B. (B) Activity of BacA farnesyl pyrophosphate in the presence or absence of PBP1B. In both (A) and (B), white symbols correspond to the phosphatase on its
own and black symbols to the phosphatase plus PBP1B. (C) Kinetic parameters (mean ± SD) obtained in three independent experiments.
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PBP1B and a phosphatases the lipid II consumption increased to 34%
(with BacA) or 63% (with PgpB), and the band corresponding to C55-P
appeared in the TLC (Fig. 6D and E). In addition, this assay showed that
BacA and PgpB were able to use the C55-PP released by PBP1B during
PG synthesis. Finally, the stimulatory effect of PgpB was higher than
that of BacA in both membrane-based assays (Fig. 6) and in the HPLC
assay in detergents (Fig. 5).
C55-PP is a potent inhibitor of PBP1B
To better understand the mechanism by which C55-PP pyropho-
sphatases stimulate PG synthesis we next investigated whether any of
the carrier lipid versions had an effect on the GTase activity of PBP1B
(Fig. 7). Commercially available C55-P had a small inhibitory effect on
PBP1B, reducing the relative GTase rate by 23% (Fig. 7B and C). C55-PP
is not commercially available and was therefore synthesized by UppS
Fig. 5. PgpB and BacA stimulate PBP1B at low concentration in the presence of Triton X-100. (A) PBP1B was incubated with radiolabelled lipid II in the presence or
absence of BacA or PgpB. The reaction was stopped by boiling. The PG was digested with the muramidase cellosyl, reduced with sodium borohydride, and the
resulting muropeptides were separated by HPLC. The concentration of PBP1B in µM is indicated in brackets. (B) Quantification of the PG products obtained in at least
three independent experiments (mean ± SD). (C) Quantification of the % peptides in cross-links obtained in at least three independent experiments (mean ± SD).
(D) Proposed structures of muropeptides in fractions 1–4 (panel A).
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from the substrates C5-PP (isopentenyl pyrophosphate, IPP) and C15-PP
(farnesyl pyrophosphate, FPP) prior to starting the GTase reaction by
addition of dansylated lipid II (Fig. S4A). Interestingly, we found that
C55-PP is a potent inhibitor of PBP1B, reducing its relative GTase rate
by 93% (Fig. 7A and C). The presence of UppS without its substrates
had no effect on PBP1B; C5-P and C15-PP without UppS caused an 40%
reduction in PBP1B activity (Fig. 7C and S4B). Importantly, the addi-
tion of active PgpB, but not the inactive version, partially restored the
Fig. 6. BacA and PgpB increase lipid II consumption by PBP1B in the membrane. The activity of PBP1B was measured in proteoliposomes with PgpB, BacA or no
phosphatase. (A) Radiolabelled lipid II was used as substrate and PG products were analysed by HPLC (as shown in Fig. 5A). The peak numbers relate to the
muropeptide structures in Fig. 5D. (B) Quantification of the PG products obtained in two independent experiments (mean ± SD). (C) Quantification of the %
peptides in cross-links obtained in two independent experiments (mean ± SD). (D) Using non-labelled lipid II and thin-layer chromatography allowed the detection
of residual lipid II, C55-P and C55-PP. Control, proteoliposomes without enzyme with added lipid II and C55-P. (E) Quantification of lipid II and C55-P from 3
independent experiments as the one in panel D. The values are mean ± SD and asterisks indicate p-value comparisons with PBP1B (*p < 0.1 and **p < 0.05). HPLC
assays were performed using E. coli polar lipids liposomes. For the TLC assay, artificial lipids were used plus LpoB(sol) was added at 4 µM.
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GTase activity of PBP1B, presumably by converting some of the C55-PP
produced by UppS to C55-P, which is less inhibitory (Fig. 7A, C, S4C
and S4D). Interestingly, PgpB also protected PBP1B from inhibition by
UppS substrates C5-PP and C15-PP most probably by depho-
sphorylating these (Fig. 7C and S4C). Hence, our data show that PBP1B
is inhibited by its product, C55-PP, which is released in GTase reactions,
and that activity can be restored by dephosphorylation of C55-PP to
C55-P.
In silico modelling of the structure of the PgpB-PBP1B complex
In order to better understand the interaction of PgpB and PBP1B, we
performed an in silico docking study using the published crystal struc-
tures of PgpB (Tong et al., 2016) and PBP1B (King et al., 2017) (Fig. 8).
The complex was built and energy-minimised as described in Materials
and Methods. The lowest energy clusters have a HADDOCK scores of
−108.3 ± 17.4 kcal mol−1 with electrostatic and Van der Waals en-
ergies of −94.3 ± 25.8 kcal mol−1 and −69.7 ± 4.8 kcal mol−1, re-
spectively. In the lowest energy model, the active sites of PgpB and the
GTase of PBP1B GTase are both on the periplasmic side of the cyto-
plasmic membrane, as has been shown experimentally. The single TM
helix of PBP1B is located between TM5 and TM1 of PgpB with extra
contacts between TM1 of PgpB and the most deeply membrane-em-
bedded region of the GTase domain of PBP1B. Additional contacts be-
tween the solvent-exposed periplasmic region of PgpB and the lowest
part of the TPase domain stabilize this complex. This orientation places
the 'donor strand'-binding region in the PBP1B GTase domain closest to
the active site of PgpB (Fig. 8B). The ‘donor strand’ lipid II is the one
whose oligosaccharide moiety is transferred to the C4 hydroxyl of the
GlcNAc moiety in the ‘acceptor’ lipid II. Once a glycosyltransferase
reaction is completed by transferring the donor strand (either lipid II or
the growing glycan chain) onto the acceptor lipid II, the resulting C55-
PP moiety has to be removed to allow the movement of the growing
chain from the acceptor to the donor site. In the presented complex
structure, the lipid carrier can easily access the active site of PgpB
which would facilitate the release of C55-PP from the GTase domain
permitting a faster polymerization of the peptidoglycan chain.
Discussion
The major bi-functional PG synthases in E. coli, PBP1A and PBP1B,
interact with monofunctional TPases (Bertsche et al., 2006, Banzhaf
et al., 2012) and are activated by outer membrane-anchored lipopro-
teins (Typas et al., 2010, Paradis-Bleau et al., 2010), and the activation
of PBP1B is modulated by components of the Tol system (Gray et al.,
2015). PBP1B also interacts with other membrane embedded proteins
including cell division protein FtsN (Müller et al., 2007) and FtsW
(Leclercq et al., 2017), which has been shown to have lipid II flippase
activity in vitro (Mohammadi et al., 2011). In this work we discovered a
connection between the two C55-PP phosphatases PgpB and BacA with
PBP1B, adding a new perspective on PG synthesis and pointing to a
functional connection between the polymerization of PG and the re-
cycling of the carrier lipid. Both phosphatases stimulated PBP1B in
proteoliposomes, suggesting that the coupling of successive membrane
steps in PG synthesis – lipid II polymerization and carrier lipid de-
phosphorylation – could be important in the cell. Indeed, the higher
sensitivity of the pgpB mutant to cefsulodin suggests an impaired cel-
lular functionality of PBP1B in the absence of PgpB.
We showed that the stimulatory effect of PgpB on PBP1B is likely
due to a physical interaction between both proteins. We obtained
contradictory results on a possible interaction of BacA with PBP1B, and
BacA stimulated PBP1B to lesser extent than PgpB. These results are
consistent with the idea that phosphatases generally stimulate PG
GTases by converting their inhibitory C55-PP product into the less in-
hibitory C55-P, and that PgpB has an additional stimulatory effect as-
sociated with its specific interaction with PBP1B.
How does PgpB stimulate PBP1B?
We observed the stimulation of PBP1B GTase by PgpB under two
different conditions, at low PBP1B concentration in detergents (Fig. 5)
and in the membrane environment of proteoliposomes (Fig. 6). In
Fig. 7. C55-PP inhibits the GTase activity of PBP1B. (A) Continuous fluores-
cence assay for GTase activity of PBP1B in the presence of C55-PP synthesized
by incubating UppS and its substrates C5-PP and C15-PP (+UppS/S). Samples
contained PgoB, PgpB(D211E) (PgpB*) or no phosphatase; control samples
contained only UppS or substrates, or the known GTase inhibitor moenomycin
(Moe). (B) GTase activity assay of PBP1B in the presence or absence of C55-P.
(C) The GTase rates obtained from the assays in (A) and (B) and control reac-
tions in Fig. S4B–D were normalised relative to the activity of PBP1B in the
absence of PgpB, UppS and its substrates. *p < 0.05; **p < 0.005. The values
are mean ± SD of at least 3 independent experiments.
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detergents, PBP1B shows higher activity under conditions where it di-
merizes (Bertsche et al., 2005) and therefore it is possible that the in-
teraction with PgpB stabilizes the more active dimer form of PBP1B. In
a membrane context, PgpB stimulated PBP1B consumption of lipid II
when incorporated in the same proteoliposomes (Fig. 6). This effect
may be explained by the removal of C55-PP by the phosphatase, which
might slow down PBP1B due to product inhibition as it happened in
detergents (Fig. 7). Interestingly, the catalytically inactive version of
PgpB also stimulated PBP1B in the membrane (Fig. 6A) while it failed to
rescue inhibition by C55-PP in detergents (Fig. 7). Hence, the inactive
PgpB(D211E) may accelerate the release of C55-PP from PBP1B
(without hydrolysing it) only in the membrane system, allowing a faster
polymerisation rate. The model structure of the PgpB-PBP1B complex
obtained by in silico docking (Fig. 8) shows a close proximity between
the active site of PgpB and the ‘donor’ lipid II binding site in PBP1B
GTase domain, supporting such a coupled mechanism.
Importance of the coupling between phosphatases and PBPs
C55-P is used to transport the precursors of several abundant cell
envelope polymers across the cell membrane, for example those for the
synthesis of PG and the O-antigen chains of LPS (Manat et al., 2014). E.
colimaintains a pool of free carrier lipid of 1.5× 105 molecules per cell,
25% of these are in the 'active' C55-P form and 75% as C55-PP
(Barreteau et al., 2009). The maintenance of the C55-P pool requires
the efficient recycling of C55-PP by four phosphatases, BacA, PgpB,
YbjG and LpxT (El Ghachi et al., 2005). The reason for this redundancy
is unclear but BacA appears to have the highest activity (and im-
portance) in the cell (El Ghachi et al., 2005) and LptX is a special case
because it transfers the phosphate moiety form C55-PP to lipid A (Touzé
et al., 2008b, El Ghachi et al., 2005).
Here we show that PgpB acts together with PBP1B and not PBP1A,
forming a tight complex, which potentially could stimulate both en-
zymes. Complex formation with PBP1B could be a means to increase the
efficiency of PgpB to dephosphorylate C55-PP immediately after the
GTase reaction at the site where it is being released. We did not detect a
substantial effect of PBP1B on the rate of C15-PP degradation by the
phosphatases (Fig. 4). However, more experiments are needed to test
the possibility that the degradation of C55-PP is faster when it is de-
livered directly from the polymerase than when it is freely diffusing in
the membrane. The interaction between PgpB and PBP1B could im-
prove the efficiency of PG polymerization in the cell membrane by
preventing inhibition by locally high concentrations of C55-PP (Fig. 7).
Our results are consistent with several possible mechanisms of stimu-
lation, which are not exclusive. The association of both proteins may (i)
accelerate the release of C55-PP from the active site of the GTase, (ii)
prevent the inhibition of the GTase by the free pool of C55-PP on the
periplasmic side of the cell membrane and/or (iii) cause an allosteric
activation of PBP1B. While further experiments are needed to assess the
contribution of each of these possibilities it is possible that C55-PP
accumulates locally at sites of PG synthesis and, hence, its fast removal
is achieved by the coupling of C55-PP phosphatases and PG synthases.
Similar mechanisms might be used in other pathways involving the use
of polyprenyl phosphates as lipid carriers for oligosaccharides across
membranes.
PgpB has been described to have a dual role in the cell. The protein
is not only involved in the dephosphorylation of C55-PP, but it also
dephosphorylates phosphatidylglycerol-phosphate (PGP), the precursor
of the most abundant anionic phospholipid in E. coli, phosphati-
dylglycerol (Tong et al., 2016). In fact, PgpB on its own is able to
sustain phosphatidylglycerol synthesis in the absence of the other PGP
phosphatases (Lu et al., 2011). This second activity raises the possibility
that PgpB triggers the synthesis of anionic phospholipids at sites of
PBP1B localization, and that the phospholipid composition could be
another factor that regulates PG growth. Interestingly, it has been re-
ported that peptidoglycan synthesis requires ongoing phospholipid
synthesis (Rodionov & Ishiguro, 1996) and that this is likely due to
disruption in lipid II transport when phospholipid synthesis is blocked
(Ehlert & Höltje, 1996). In fact, it has been recently reported that lipid
synthesis is a major determinant of bacterial cell size, independently of
the stringent response by ppGpp (Vadia et al., 2017). Further studies
are needed to decipher the possible role of phospholipids in the
Fig. 8. Docking model of the PgpB-PBP1B complex. The complex between PgpB and PBP1B was built and energy-minimised with HADDOCK/CNS programs starting
from the initial coordinates of the E. coli structures (PDB codes 5JWY and 5HLD). (A) Structure of the lowest energy complex depicted in its surface representation.
PgpB is shown in grey, the domains of PBP1B are coloured in blue (GTase), green (TPase), cyan (UB2H), and light blue (trans-membrane helix). Catalytic residues in
PgpB (H163, H207, D211) and PBP1B (E233 in the GTase domain and S510 in the TPase domain) are coloured in red. (B) A zoomed-in view of active site regions
showing the proximity between active site of PgpB and the ‘donor’ lipid II binding site in the GTase domain of PBP1B.
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regulation of PG synthesis.
Conclusions
To our knowledge we report here for the first time an interaction
between a membrane-anchored oligosaccharide glycosyltransferase and
a polyprenyl pyrophosphate phosphatase. The interaction between the
PG synthase PBP1B and the membrane phosphatase PgpB stimulates PG
synthesis in membrane systems, presumably due to the faster release of
the carrier lipid C55-PP from the active site of the polymerase, and by
preventing substrate inhibition by C55-PP.
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